Effervescent tablet for regulating blood sugar as well as preparation method and application of effervescent tablet

Abstract

The invention relates to the technical field of health-care beverages, and particularly provides effervescent tablets for regulating blood sugar as well as a preparation method and application of the effervescent tablets. The effervescent tablet comprises the following raw materials in parts by weight: 20-30 parts of grifola frondosa polysaccharide, 10-25 parts of ganoderma lucidum polysaccharide, 5-15 parts of phellinus igniarius polysaccharide, 8-12 parts of citric acid, 15-30 parts of sodium bicarbonate, 10-15 parts of a filling agent, 3-5 parts of an adhesive, 0.5-2 parts of a sweetening agent and 1-3 parts of a lubricating agent, adopts a direct tabletting technology, and comprises the steps of material mixing, drying, uniform mixing and tabletting. The process is simplified, manpower, time, water and electricity are saved, the production cost is greatly reduced, and the blood sugar reducing effect is obvious through the steps of adjusting the reasonable amount of the acid agent and the reasonable amount of the alkali agent and finishing the granules.

Description

Technical Field

[0001] This invention relates to the field of health beverage technology, specifically providing a blood sugar regulating effervescent tablet, its preparation method, and its application. Background Technology

[0002] Diabetes mellitus is a metabolic disease characterized by high blood sugar, with a high incidence worldwide. It often leads to serious complications such as nerve damage, diabetic nephropathy, and cardiovascular disease. Diabetes mellitus presents in various forms and requires a long treatment period. Compared to traditional hypoglycemic drugs, products developed based on food and medicine ingredients have gained widespread attention due to their high safety, lack of side effects, stability, and mild effects.

[0003] Effervescent tablets are tablets that disintegrate upon contact with water. The disintegrant reacts to release carbon dioxide, which promotes the rapid dissolution of the active ingredients. They are convenient to take and carry, have high bioavailability, and taste good. They are especially suitable for children, the elderly, and patients who have difficulty swallowing solid dosage forms.

[0004] There are three existing methods for preparing effervescent tablets: wet granulation, dry granulation, and direct compression. Wet granulation involves mixing raw material powders with a binder to form a soft mass, followed by granulation and drying. However, this method uses a trough mixer to prepare the soft mass, which is then granulated using a vibrating granulator, and finally dried in a drying oven. This method has low output, high intensity, serious pollution, long production cycle, and large equipment footprint. Dry granulation involves pressing a powder mixture into large tablets, followed by crushing and granulation to the desired particle size. It is suitable for heat- and moisture-sensitive materials, but the compression process generates significant dust, easily causing cross-contamination, and the dissolution rate of the compressed granules is slow, making it unsuitable for water-soluble effervescent tablets.

[0005] Patent number 202211034831.1, entitled "A Kind of Effervescent Tablet with Health-Promoting Functions and Its Preparation Method," discloses that the effervescent tablet comprises the following parts by weight: 2-8 parts of simulated wild Ganoderma lucidum powder, 20-30 parts of disintegrant, 58-64 parts of filler, 1-4 parts of solubilizer, and 1-2 parts of binder. After sieving and weighing the above raw materials and excipients, acid-base granulation is performed separately. The acid and alkali granules are then sieved, dried, and granulated, and finally compressed into tablets to obtain the simulated wild Ganoderma lucidum effervescent tablets. The problems are as follows: 1. Because the raw materials used are Ganoderma lucidum spore powder and fruiting body extract after spore release, floating matter and sediment appear during the dissolution process of the prepared effervescent tablets; 2. The preparation process of effervescent tablets involves acid and alkali granulation, sieving, and drying, which is complex and time-consuming; 3. No lubricant is used, so the surface smoothness of the effervescent tablets may be insufficient; 4. The amount of acid and alkali added to the effervescent tablets is the same, and the disintegration effect is generally poor, so a solubilizer needs to be added, and the raw materials used are complex.

[0006] Patent No. 2016104625735, entitled "A Blood Sugar Lowering Effervescent Herbal Tea Tablet and Its Preparation Method," discloses that the effervescent herbal tea tablet comprises the following components: 12-16 parts of a common herbal tea extract, 3-6 parts of black fungus polysaccharide, 2-4 parts of laver polysaccharide, and 1-2 parts of chitosan. The common herbal tea extract is obtained by extracting 6-10 parts of buckwheat, 5-10 parts of snow chrysanthemum, 3-6 parts of corn silk, 3-6 parts of pumpkin seeds, 4-8 parts of dandelion, 4-10 parts of poria cocos, 5-8 parts of winter melon peel, and 3-7 parts of peanut shells. The added black fungus polysaccharide, laver polysaccharide, and chitosan are all polysaccharide components. Biological polysaccharides have various physiological functions. Adding polysaccharide components to the effervescent herbal tea tablet increases viscosity, allowing for a reduction in the amount of binder used during the tablet production process, which is more in line with health trends. The problems are as follows: 1. Because the amount of acid and alkali used is the same, the disintegration effect is generally poor; 2. Due to the unreasonable drug compatibility, the hypoglycemic effect is not obvious; 3. Although acid and alkali granulation is not performed separately, the preparation process is still complicated because the preparation of sodium bicarbonate coating and the addition of binder require ultrasonic treatment. Summary of the Invention

[0007] In view of this, the present invention provides a blood sugar regulating effervescent tablet, its preparation method and application, which adopts direct tableting technology, including several steps such as mixing, drying, mixing and tableting. By adjusting the appropriate amount of acid and alkali and the granulation step, the process is simplified, saving manpower, time and water and electricity, greatly reducing production costs and improving the blood sugar lowering effect.

[0008] To achieve the above objectives, the present invention provides the following technical solution: a blood sugar regulating effervescent tablet, wherein the effervescent tablet comprises the following raw materials in parts by weight: 20-30 parts of Grifola frondosa polysaccharide, 10-25 parts of Ganoderma lucidum polysaccharide, 5-15 parts of Phellinus linteus polysaccharide, 8-12 parts of citric acid, 15-30 parts of sodium bicarbonate, 10-15 parts of filler, 3-5 parts of binder, 0.5-2 parts of sweetener, and 1-3 parts of lubricant.

[0009] Furthermore, the filler is lactose.

[0010] Furthermore, the adhesive is a 3% PVP-anhydrous ethanol solution.

[0011] Furthermore, the sweetener is sucralose.

[0012] Furthermore, the lubricant is PEG6000.

[0013] The steps of a method for preparing a blood glucose regulating effervescent tablet are as follows:

[0014] 1) Mixing: Sift the Grifola frondosa polysaccharide, Ganoderma lucidum polysaccharide, Phellinus linteus polysaccharide, citric acid, sodium bicarbonate, filler and sweetener and mix them evenly;

[0015] 2) Drying: After bonding with adhesive, dry in an oven at 70~80℃;

[0016] 3) Granulation: The lubricant is heated and melted in a 70°C water bath, and the dried product from step (2) is added to it, mixed well and then granulated;

[0017] 4) Tableting: Tableting can be performed using a rotary tablet press when the temperature is 18~25℃ and the relative humidity is below 50%.

[0018] Furthermore, in step 1), the weight ratio of Grifola frondosa polysaccharide, Ganoderma lucidum polysaccharide, and Phellinus linteus polysaccharide is 3:2:1, and the weight ratio of citric acid and sodium bicarbonate is 1:2.

[0019] Furthermore, in step 4), the tablet press rotates at a speed of 12-20 rpm and the pressure is 200-300 kN, resulting in effervescent tablets with a hardness of 12 kg / cm². 2 .

[0020] Application of effervescent tablets prepared by the above method in blood glucose regulation products.

[0021] Compared with the prior art, the present invention has the following beneficial effects:

[0022] 1. This invention uses edible and medicinal fungi such as Grifola frondosa polysaccharide, Ganoderma lucidum polysaccharide and Phellinus linteus polysaccharide as the main components, which are highly safe. At the same time, by adding sweeteners to mask the taste of the edible and medicinal fungi themselves, a good taste is guaranteed, the consumption experience is good, and it is easy for the public to accept.

[0023] 2. The raw materials used in this invention have no toxic side effects and can be used as a safe blood sugar lowering product to lower blood sugar.

[0024] 3. This invention uses a 3% PVP aqueous solution as a binder and PEG6000 as a lubricant, which gives the effervescent tablets good adhesion and hardness, avoids the use of common non-water-soluble lubricant magnesium stearate, makes the tablet surface smooth, and solves the problem of floating matter or sediment when the effervescent tablets are dissolved.

[0025] 4. This invention eliminates the steps of separately coating the acid source and the alkali source. At the same time, the granulation and tableting steps are simple and do not require ultrasonic treatment, saving manpower, time, water and electricity, and greatly reducing production costs. Detailed Implementation

[0026] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be further described in detail below through embodiments. It should be understood that the specific embodiments described herein are merely illustrative and not intended to limit the scope of the invention.

[0027] Example 1:

[0028] A blood sugar regulating effervescent tablet comprises the following raw materials in parts by weight: 30 parts of Grifola frondosa polysaccharide, 20 parts of Ganoderma lucidum polysaccharide, 10 parts of Phellinus linteus polysaccharide, 8 parts of citric acid, 16 parts of sodium bicarbonate, 10 parts of lactose, 3 parts of 3% PVP-anhydrous ethanol solution, 0.5 parts of sucralose, and 1 part of PEG6000.

[0029] The preparation method of a blood glucose regulating effervescent tablet includes the following steps:

[0030] 1) Mixing: Sift together the Grifola frondosa polysaccharide, Ganoderma lucidum polysaccharide, Phellinus linteus polysaccharide, citric acid, sodium bicarbonate, lactose and sucralose and mix them evenly.

[0031] 2) Drying: After bonding with a 3% PVP-anhydrous ethanol solution, dry in an oven at 70℃;

[0032] 3) Granulation: Heat PEG6000 in a 70℃ water bath to melt it, add the dried product from step (2) to it, mix well and then granulate;

[0033] 4) Tableting: Tableting can be performed using a rotary tablet press when the temperature is 22℃ and the relative humidity is below 50%.

[0034] The tablet press rotates at 15 rpm and operates at a pressure of 200 kN, producing effervescent tablets with a hardness of 12 kg / cm². 2 .

[0035] Example 2:

[0036] A blood sugar regulating effervescent tablet comprises the following raw materials in parts by weight: 27 parts of Grifola frondosa polysaccharide, 18 parts of Ganoderma lucidum polysaccharide, 9 parts of Phellinus linteus polysaccharide, 10 parts of citric acid, 20 parts of sodium bicarbonate, 15 parts of lactose, 5 parts of 3% PVP-anhydrous ethanol solution, 1 part of sucralose, and 2 parts of PEG6000.

[0037] The preparation method of a blood glucose regulating effervescent tablet includes the following steps:

[0038] 1) Mixing: Sift together the Grifola frondosa polysaccharide, Ganoderma lucidum polysaccharide, Phellinus linteus polysaccharide, citric acid, sodium bicarbonate, lactose and sucralose and mix them evenly.

[0039] 2) Drying: After bonding with 3% PVP-anhydrous ethanol solution, dry in an oven at 75℃;

[0040] 3) Granulation: Heat PEG6000 in a 70℃ water bath to melt it, add the dried product from step (2) to it, mix well and then granulate;

[0041] 4) Tableting: Tableting can be performed using a rotary tablet press when the temperature is 23℃ and the relative humidity is below 50%.

[0042] The tablet press rotates at 18 rpm and operates at a pressure of 280 kN, producing effervescent tablets with a hardness of 12 kg / cm². 2 .

[0043] Example 3:

[0044] A blood sugar regulating effervescent tablet comprises the following raw materials in parts by weight: 24 parts of Grifola frondosa polysaccharide, 16 parts of Ganoderma lucidum polysaccharide, 8 parts of Phellinus linteus polysaccharide, 11 parts of citric acid, 22 parts of sodium bicarbonate, 13 parts of lactose, 5 parts of 3% PVP-anhydrous ethanol solution, 0.5 parts of sucralose, and 2 parts of PEG6000.

[0045] The preparation method of a blood glucose regulating effervescent tablet includes the following steps:

[0046] 1) Mixing: Sift together the Grifola frondosa polysaccharide, Ganoderma lucidum polysaccharide, Phellinus linteus polysaccharide, citric acid, sodium bicarbonate, lactose and sucralose and mix them evenly.

[0047] 2) Drying: After bonding with 3% PVP-anhydrous ethanol solution, dry in an oven at 78℃;

[0048] 3) Granulation: Heat PEG6000 in a 70℃ water bath to melt it, add the dried product from step (2) to it, mix well and then granulate;

[0049] 4) Tableting: Tableting can be performed using a rotary tablet press when the temperature is 22℃ and the relative humidity is below 50%.

[0050] The tablet press rotates at 12 rpm and operates at a pressure of 200 kN, producing effervescent tablets with a hardness of 12 kg / cm². 2 .

[0051] Example 4:

[0052] A blood sugar regulating effervescent tablet comprises the following raw materials in parts by weight: 21 parts of Grifola frondosa polysaccharide, 14 parts of Ganoderma lucidum polysaccharide, 7 parts of Phellinus linteus polysaccharide, 12 parts of citric acid, 24 parts of sodium bicarbonate, 14 parts of lactose, 4 parts of 3% PVP-anhydrous ethanol solution, 1.5 parts of sucralose, and 2 parts of PEG6000.

[0053] The preparation method of a blood glucose regulating effervescent tablet includes the following steps:

[0054] 1) Mixing: Sift together the Grifola frondosa polysaccharide, Ganoderma lucidum polysaccharide, Phellinus linteus polysaccharide, citric acid, sodium bicarbonate, lactose and sucralose and mix them evenly.

[0055] 2) Drying: After bonding with 3% PVP-anhydrous ethanol solution, dry in an oven at 70℃;

[0056] 3) Granulation: Heat PEG6000 in a 70℃ water bath to melt it, add the dried product from step (2) to it, mix well and then granulate;

[0057] 4) Tableting: Tableting can be performed using a rotary tablet press when the temperature is 20℃ and the relative humidity is below 50%.

[0058] The tablet press rotates at 18 rpm and operates at a pressure of 270 kN, producing effervescent tablets with a hardness of 12 kg / cm². 2 .

[0059] This invention utilizes Grifola frondosa polysaccharide to enhance insulin sensitivity through the PPARγ pathway, Ganoderma lucidum polysaccharide to activate the AMPK pathway and promote glucose metabolism, and Phellinus linteus polysaccharide to inhibit α-glucosidase and reduce glucose absorption. The synergistic effect of these three components enhances the hypoglycemic effect.

[0060] The weight ratio of the three polysaccharides was: Grifola frondosa polysaccharide: Ganoderma lucidum polysaccharide: Phellinus linteus polysaccharide = 3:2:1. Grifola frondosa polysaccharide had a relatively higher content, resulting in a clear hypoglycemic effect and rapid onset of action. In vitro experiments showed that this ratio had the highest inhibition rate against α-glucosidase.

[0061] The effervescent tablets of this invention are designed to weigh 2g.

[0062] Selection test of raw materials for this invention:

[0063] 1) Selection of fillers: Lactose, soluble starch, sucrose and lactose were selected as pre-selected fillers, and their hygroscopicity and solubility were used as evaluation indicators.

[0064]

[0065] Results: Lactose has the lowest hygroscopicity, the effervescent tablets produce a clear liquid after effervescence, and it has a sweet taste, thus having a flavoring effect. Therefore, lactose was chosen as the filler.

[0066] 2) Selection of lubricant: Water-soluble lubricant should be selected for the preparation of oral effervescent tablets. Sodium carboxymethyl cellulose and PEG6000 are pre-selected lubricants. Disintegration time, hardness and appearance of effervescent tablets are used as evaluation indicators.

[0067]

[0068] Results: PEG6000 showed a shorter disintegration time, better hardness, smoother and finer appearance, and more uniform color when used as a lubricant than sodium carboxymethyl cellulose. Therefore, PEG6000 was selected as the lubricant in subsequent experiments.

[0069] 3) Investigation of the ratio of acid source to alkali source: A larger amount of acid source results in the fastest dissolution of effervescent tablets, while a larger amount of alkali source leads to the optimal gas production. The ratios of citric acid to sodium bicarbonate were designed to be 1.5:1, 1:1, 1:1.5, 1:2, and 1:2.5, with other ingredients kept constant. Three batches were prepared in parallel for each group. Disintegration time, foaming volume, and pH were used as evaluation indicators to investigate the optimal ratio of citric acid (acid source) to sodium bicarbonate (alkali source).

[0070]

[0071] Result: The optimal ratio of acid source to alkali source was determined to be 1:2.

[0072] 4) Adhesives: 3% PVP-water solution, 3% PVP-ethanol solution, and 10% starch solution were designed as pre-selected adhesives, and disintegration time, 30-day hardness, and granulation were used as evaluation indicators for evaluation.

[0073]

[0074] Results: The effervescent tablets prepared with 3% PVP-water solution had good disintegration time, hardness and particle size. Therefore, 3% PVP-anhydrous ethanol solution was selected as the binder for Grifola frondosa polysaccharide effervescent tablets.

[0075] 5) Evaluation of Sweeteners: A good taste can improve the user compliance of effervescent tablets. To obtain a better taste, an appropriate amount of sweetener needs to be added to the effervescent tablet formulation for flavoring. Sucralose has no calories, a pure sweet taste, and is highly safe; therefore, this study selected sucralose as the sweetener. The designed dosages were 0.5%, 0.75%, 1.0%, 1.25%, and 1.5%, respectively. With other conditions kept constant, three batches of effervescent tablets were prepared in parallel for each group, and the degree of sweetness was used as the evaluation index.

[0076]

[0077] Results: If the amount of sucralose added is less than 0.75%, the sweetness is too weak; if the amount added is greater than 0.75%, the sweetness is too strong. Therefore, the amount of sucralose added is chosen to be 0.75%.

[0078] Example 1 is the optimal solution of the present invention. The effervescent tablets prepared have a smooth surface, uniform color, and disintegration time, pH value and other properties that meet the quality requirements of the Chinese Pharmacopoeia. Furthermore, the effervescent tablets are clear after dissolving and have a good taste, indicating that the formula has good reliability and feasibility.

[0079] The efficacy study of effervescent tablets in Example 1 (mouse experiment on blood glucose regulation effect).

[0080] Experimental methods:

[0081] 1) Experimental drugs: The effervescent tablets were disintegrated in 200mL of water. After complete disintegration, the dosage was calculated according to the weight of the mice. The high-dose group was administered 2mL (400mg / kg) by gavage, the medium-dose group was administered 1.5mL (300mg / kg) by gavage, and the low-dose group was administered 1mL (200mg / kg) by gavage.

[0082] 2) Animals: All mice were SPF grade, 4-5 weeks old, male, and weighed 20±2g. All mice were housed in a temperature- and humidity-controlled SPF animal chamber at (22±2)℃ and 52%±3% humidity, with a 12-hour light-dark cycle. Ten mice were randomly selected as the blank control group, and the rest were used to establish a diabetic mouse model.

[0083] ① Preparation of a diabetic mouse model: Mice were acclimatized for 1 week, fasted for 12 hours, and then intraperitoneally injected with streptozotocin (STZ) (dissolved in 0.1 mol / L citrate buffer, prepared immediately before use) for 3 consecutive days at a dose of 50 mg / kg, in conjunction with a high-sugar, high-fat diet. A diabetic model was established after 72 hours. Fasting blood glucose was measured (after 12 hours of fasting). Mice with blood glucose levels greater than 11.1 mmol / L, exhibiting the typical symptoms of diabetes (polyuria, polydipsia, polyphagia, and weight loss), were considered to have successfully developed the experimental diabetic model.

[0084] High-sugar, high-fat feed formulation: 66.5% (by weight) of basal feed, 10% of lard, 20% of sucrose, 2.5% of cholesterol, and 1% of sodium cholate.

[0085] ② The experimental mice were randomly divided into 6 groups of 10 mice each, including a normal control group (gavaged with saline), a diabetic model group (gavaged with saline), a high-dose polysaccharide treatment group, a medium-dose polysaccharide treatment group, a low-dose polysaccharide treatment group, and a positive control group (metformin). The normal control group and the diabetic model group were given an equal volume of saline by gavage. After grouping, the mice were administered the corresponding concentration of the drug or an equal volume of saline by gavage for 28 consecutive days starting the next day. After gavage, the mice were fasted for 12 hours but allowed free access to water. Their body weight was measured, and their fasting blood glucose was measured.

[0086] Measurement: ① During the experiment, observe and record the changes in the mice's food intake and water intake every day, and measure their body weight and fasting blood glucose level once a week (blood was collected from the tail tip and measured with a blood glucose meter).

[0087] ② Oral glucose tolerance test (OGTT): After 28 days of intervention, rats were fasted (but allowed water) for 12 hours, and oral glucose resistance tests were performed on 5 groups of rats. Fasting blood glucose levels were measured first, and then 2 g / kg glucose solution was administered by gavage. Blood glucose levels were then measured at 30, 60, 120, and 180 min.

[0088] Experimental results:

[0089] Table 1. Effects of effervescent tablets administered by gavage on fasting blood glucose in normal mice.

[0090]

[0091] Results: Fasting blood glucose was significantly lower in the normal polysaccharide group compared with that in the normal control group (P<0.05).

[0092] Table 2. Effects of effervescent tablets administered by gavage on fasting blood glucose in diabetic mice.

[0093]

[0094] Results: High, medium and low dose groups all significantly reduced fasting blood glucose in diabetic mice (P<0.05), with the high dose treatment group showing an effect close to that of the positive control group (metformin).

[0095] Table 3. Effects of effervescent tablets administered via gavage on glucose tolerance in diabetic mice.

[0096]

[0097] Results: The area under the blood glucose curve in the high-dose and medium-dose groups was significantly lower than that in the control group, which significantly reduced glucose tolerance in diabetic mice. The low-dose group did not show significant effect, but there was a downward trend.

[0098] Conclusion: High, medium, and low dose groups all significantly reduced fasting blood glucose in STZ-treated diabetic mice, with the high-dose treatment group showing an effect close to that of the positive control group (metformin). The area under the blood glucose curve in the high-dose and medium-dose groups was significantly lower than that in the control group, indicating a significant reduction in glucose tolerance in diabetic mice. The low-dose group did not show a significant effect, but it did show a downward trend. These results indicate that the intervention has a blood glucose-lowering effect.

[0099] 3) There is a close relationship between glucose metabolism and lipid metabolism in animal bodies. In diabetic model mice, hyperglycemia is accompanied by secondary hyperlipidemia. Therefore, correcting glucose and lipid metabolism disorders is an important means of treating diabetes and its complications.

[0100] Measurement: Total cholesterol, triglycerides, and high-density lipoprotein were measured using a kit.

[0101] After 28 days of intervention, the patient fasted for 12 hours, underwent ether anesthesia, and blood was drawn from the orbital venous plexus. The blood was centrifuged at 3000 rpm for 15 minutes, and the collected serum was stored at -20°C. Serum levels of total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were measured. The Arteriosclerosis Index (AI) = (TC - HDL-C) / HDL-C

[0102]

[0103] Results: Both the high-dose and medium-dose treatment groups had significant effects on lipid regulation in diabetic mice (P<0.01). The effect of the high-dose treatment group was close to that of the positive control group (atorvastatin), while the low-dose treatment group had no significant regulatory effect.

[0104] The above results demonstrate that the present invention can effectively lower blood sugar, and the raw materials used in the present invention have no toxic side effects. In other words, the present invention can be used as a safe blood sugar lowering product, which is in line with the current health trend and is conducive to market promotion.

[0105] The above embodiments are only the preferred embodiments of the present invention and do not limit any modifications to the present invention. Any modifications, changes and optimizations made according to the embodiments of the present invention shall fall within the scope of protection of the present invention.

Claims

1. A blood sugar regulating effervescent tablet, characterized in that, The effervescent tablets comprise the following raw materials in parts by weight: 20-30 parts of Grifola frondosa polysaccharide, 10-25 parts of Ganoderma lucidum polysaccharide, 5-15 parts of Phellinus linteus polysaccharide, 8-12 parts of citric acid, 15-30 parts of sodium bicarbonate, 10-15 parts of filler, 3-5 parts of binder, 0.5-2 parts of sweetener, and 1-3 parts of lubricant.

2. The blood sugar regulating effervescent tablet according to claim 1, characterized in that, The filler is lactose.

3. A blood glucose regulating effervescent tablet according to claim 1 or 2, characterized in that, The adhesive is a 3% PVP-anhydrous ethanol solution.

4. The blood sugar regulating effervescent tablet according to claim 3, characterized in that, The sweetener mentioned is sucralose.

5. The blood sugar regulating effervescent tablet according to claim 4, characterized in that, The lubricant is PEG6000.

6. The method for preparing a blood sugar regulating effervescent tablet according to claim 1, characterized in that, The steps are as follows: 1) Mixing: Sift the Grifola frondosa polysaccharide, Ganoderma lucidum polysaccharide, Phellinus linteus polysaccharide, citric acid, sodium bicarbonate, filler and sweetener and mix them evenly; 2) Drying: After bonding with adhesive, dry in an oven at 70~80℃; 3) Granulation: The lubricant is heated and melted in a 70°C water bath, and the dried product from step 2) is added to it, mixed well, and then granulated. 4) Tableting: Tableting can be performed using a rotary tablet press when the temperature is 18~25℃ and the relative humidity is below 50%.

7. The method for preparing a blood sugar regulating effervescent tablet according to claim 6, characterized in that, In step 1), the weight ratio of Grifola frondosa polysaccharide, Ganoderma lucidum polysaccharide, and Phellinus linteus polysaccharide is 3:2:1, and the weight ratio of citric acid and sodium bicarbonate is 1:

2.

8. The method for preparing a blood sugar regulating effervescent tablet according to claim 7, characterized in that, In step 4), the tablet press rotates at a speed of 12-20 rpm and the pressure is 200-300 kN, producing effervescent tablets with a hardness of 12 kg / cm². 2 .

9. The application of the effervescent tablets prepared according to the method described in claim 6 in blood glucose regulation products.

Images